BR112023018652A2 - Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis - Google Patents
Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveisInfo
- Publication number
- BR112023018652A2 BR112023018652A2 BR112023018652A BR112023018652A BR112023018652A2 BR 112023018652 A2 BR112023018652 A2 BR 112023018652A2 BR 112023018652 A BR112023018652 A BR 112023018652A BR 112023018652 A BR112023018652 A BR 112023018652A BR 112023018652 A2 BR112023018652 A2 BR 112023018652A2
- Authority
- BR
- Brazil
- Prior art keywords
- risperidone
- injectable formulation
- long
- biodegradable polymers
- action
- Prior art date
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001534 risperidone Drugs 0.000 title abstract 4
- 239000007972 injectable composition Substances 0.000 title abstract 3
- 229920002988 biodegradable polymer Polymers 0.000 title abstract 2
- 239000004621 biodegradable polymer Substances 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 229920000359 diblock copolymer Polymers 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162272P | 2021-03-17 | 2021-03-17 | |
| IB2021052248 | 2021-03-17 | ||
| US202163208860P | 2021-06-09 | 2021-06-09 | |
| US202163270174P | 2021-10-21 | 2021-10-21 | |
| PCT/EP2022/057009 WO2022195018A1 (en) | 2021-03-17 | 2022-03-17 | Long acting injectable formulation comprising risperidone and biodegradable polymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018652A2 true BR112023018652A2 (pt) | 2023-10-03 |
Family
ID=81307068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018652A BR112023018652A2 (pt) | 2021-03-17 | 2022-03-17 | Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240148641A1 (https=) |
| EP (1) | EP4308077A1 (https=) |
| JP (1) | JP2024511353A (https=) |
| KR (1) | KR20230158088A (https=) |
| AU (1) | AU2022236485A1 (https=) |
| BR (1) | BR112023018652A2 (https=) |
| CA (1) | CA3208006A1 (https=) |
| IL (1) | IL304980A (https=) |
| MX (1) | MX2023010925A (https=) |
| WO (1) | WO2022195018A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026501805A (ja) * | 2023-01-10 | 2026-01-16 | メドインセルル エス．エー． | オランザピン組成物及び使用の方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012010195A2 (pt) * | 2009-10-30 | 2016-04-26 | Janssen Pharmaceutica Nv | regime de dosagem associado a ésteres de paliperidona injetável de longa ação |
| US10463607B2 (en) * | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| KR101424163B1 (ko) * | 2010-12-24 | 2014-08-01 | 주식회사 삼양바이오팜 | 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법 |
| US9023897B2 (en) * | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| EP2866837B1 (en) | 2012-06-27 | 2022-12-14 | Medincell S.A. | Biodegradable drug delivery for hydrophobic compositions |
| US20190015415A1 (en) * | 2015-09-30 | 2019-01-17 | Indivior Uk Limited | Methods for treating schizophrenia |
| CN107213136B (zh) * | 2017-06-07 | 2021-06-01 | 广州帝奇医药技术有限公司 | 一种长效缓释药物制剂及其制备方法 |
| WO2020154315A1 (en) * | 2019-01-22 | 2020-07-30 | Indivior Uk Limited | Methods for treating schizophrenia |
| MX2022003051A (es) * | 2019-09-13 | 2022-06-14 | Medincell S A | Formulaciones para la administracion de farmacos. |
-
2022
- 2022-03-17 JP JP2023556936A patent/JP2024511353A/ja active Pending
- 2022-03-17 IL IL304980A patent/IL304980A/en unknown
- 2022-03-17 KR KR1020237035519A patent/KR20230158088A/ko active Pending
- 2022-03-17 CA CA3208006A patent/CA3208006A1/en active Pending
- 2022-03-17 US US18/281,392 patent/US20240148641A1/en active Pending
- 2022-03-17 WO PCT/EP2022/057009 patent/WO2022195018A1/en not_active Ceased
- 2022-03-17 BR BR112023018652A patent/BR112023018652A2/pt unknown
- 2022-03-17 MX MX2023010925A patent/MX2023010925A/es unknown
- 2022-03-17 AU AU2022236485A patent/AU2022236485A1/en active Pending
- 2022-03-17 EP EP22716046.2A patent/EP4308077A1/en active Pending
-
2024
- 2024-02-23 US US18/585,349 patent/US12329851B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023010925A (es) | 2023-09-27 |
| AU2022236485A1 (en) | 2023-08-24 |
| US12329851B2 (en) | 2025-06-17 |
| EP4308077A1 (en) | 2024-01-24 |
| WO2022195018A1 (en) | 2022-09-22 |
| JP2024511353A (ja) | 2024-03-13 |
| US20240148641A1 (en) | 2024-05-09 |
| KR20230158088A (ko) | 2023-11-17 |
| US20240325293A1 (en) | 2024-10-03 |
| CA3208006A1 (en) | 2022-09-22 |
| IL304980A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521430792B1 (ar) | مركبات مضادة للفيروسات محتوية على نيتريل | |
| BR112022020841A2 (pt) | Inibidores de kras tricíclicos fundidos | |
| PH12017500725B1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| BRPI0714055B8 (pt) | compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo | |
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| DE60222137D1 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
| EP4342532A3 (en) | Antiplatelet drugs and uses thereof | |
| CY1108018T1 (el) | Μεθοδος και φαρμακευτικο σκευασμα για την αντιμετωπιση της αντιστασης στα αντιυπερτασικα φαρμακα και για σχετικες παθησεις | |
| BR112015030723A2 (pt) | compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase | |
| BR112022004535A2 (pt) | Formulações de entrega de fármaco | |
| MX2021003150A (es) | Agentes monomericos y multimericos contra el vhb. | |
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| BR112021021826A8 (pt) | Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4 | |
| ATE544354T1 (de) | Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen | |
| BR112023002295A2 (pt) | Terapia de combinação | |
| BR112023016678A2 (pt) | Inibidores de tyk2 e usos dos mesmos | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| BR112023018652A2 (pt) | Formulação injetável de ação prolongada compreendendo risperidona e polímeros biodegradáveis | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112022025920A2 (pt) | Tratamento de artrite reumatoide | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| HRP20231299T1 (hr) | Inhibitori pi3k p-delta 110 za uporabu u isporuci virusa u liječenju raka |